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Abstract
Background: Opioid analgesics are generally used to combat the pain associated with cancerous
conditions. These agents not only inhibit respiratory function and cause constipation, but also
induce other significant side effects such as addiction and tolerance, all of which further contribute
to a reduced quality of life for cancer patients. Thus, in the present study, the effects of electro-
acupuncture treatment (EA) on mechanical allodynia were examined in a cancer pain mouse model.
Methods: In order to produce a neuropathic cancer pain model, S-180 sarcoma cells were
inoculated around the sciatic nerve of left legs of Balb/c mice. Magnetic Resonance Imaging (MRI)
scanning confirmed the mass of S-180 cancer cells embedded around the sciatic nerve. Mechanical
allodynia was most consistently induced in the mouse sarcoma cell line S-180 (2 × 106sarcoma
cells)-treated group compared to all the other groups studied. EA stimulation (2 Hz) was
administered daily to ST36 (Zusanli) of S-180 bearing mice for 30 min for 9 days after S-180
inoculation.
Results:  EA treatment significantly prolonged paw withdrawal latency from 5 days after
inoculation. It also shortened the cumulative lifting duration from 7 days after inoculation,
compared to the tumor control. Also, the overexpression of pain peptide substance P in the dorsal
horn of the spinal cord was significantly decreased in the EA-treated group compared to the tumor
control on Day 9 post inoculation. Furthermore, EA treatment effectively increased the
concentration of β-endorphin in blood and brain samples of the mice to a greater extent than that
of the tumor control as well as the normal group. The concentration of β-endorphin for EA
treatment group increased by 51.457% in the blood and 12.6% in the brain respectively, compared
to the tumor control group.
Conclusion: The findings of this study suggest that a S-180 cancer pain model is useful as a
consistent and short time animal model. It also indicated that EA treatment could be used as an
alternative therapeutic method for cancer pain due to a consequent decrease in substance P and
increase in β-endorphin levels.
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Background
Pain is a frequent problem in cancer patients. The analge-
sic ladder for cancer-related pain provided by the WHO
involves progressing from non-opioid (e.g., acetami-
nophen, ibuprofen), weak opioid (e.g., codeine), and
finally to strong opioid (e.g., morphine, fentanyl) inter-
vention for pain relief [1]. Some studies have been
reported that opioid switching therapy reduced side
effects and produced a reduction in pain level [2-4]. But,
unfortunately, opioid analgesics often produce poor pain
relief against neuropathic cancer pain and also induce
adverse side effects such as hormone (e.g., ACTH, cortisol,
LH and testosterone) secretion, neurotransmitter (e.g.,
nicotine, adenosine, GABA and cholecystokinine) release,
feeding, gastrointestinal motility, and respiratory activity
[5].
Thus, safe and effective complementary therapies for can-
cer pain have recently been suggested [5-7]. Generally, of
the three types of somatic, visceral and neuropathic cancer
pain conditions, neuropathic pain is the most predomi-
nant in cancer patients due to compression or infiltration
of peripheral nerves by malignant tumors [6,8]. Neuro-
pathic pain resulting from nerve injury is characterized by
spontaneous pain, allodynia (the perception of normally
innocuous stimuli as painful) and hyperalgesia (an
increased sensitivity to painful stimuli). However, an ani-
mal model for neuropathic cancer pain still remains
unclear regarding cancer cell and animal type.
Although acupuncture has a long history, its scientific
evaluation has only begun rather recently. Acupuncture
treatment or electro-acupuncture has been applied to treat
a wide range of symptoms, with some success. Electro-
acupuncture at acupoint [9]ST36 has been reported to
relieve pain and reduce inflammation and cerebral
ischemia [10,11]. Early scientific work on manual and
electrical stimulation on ST36 was carried out by many
researchers [12-16].
The aim of the present study was to evaluate the effects of
electro-acupuncture treatment on mechanical allodynia
in a mouse model of neuropathic cancer pain, using S-180
sarcoma cells. The analgesic mechanism of this procedure
was elucidated in the dorsal horn of the spinal cord of
mice using immunohistochemistry for substance P and
enzyme immunoassay (EIA) for β-endorphin in blood
and brain of mice.
Methods
Animals
Male BALB/c mice weighing 25–30 g were purchased from
Daehan Bio Link. The animals were maintained under
laboratory conditions of temperature, humidity, and
light. Mice were maintained on a 12:12 h dark-light cycle
with food and water ad libitum. The animal protocols were
approved by an institutional Animal care and use com-
mittee at Kyung Hee University.
Cell Culture
S-180 sarcoma cells (ATCC CCL-8) were grown in Dul-
becco's Modified Eagle Medium (DMEM;Gibco BRL,
Grand Island, NY) with 100 mL/L heat inactivated (30
min at 56°C) fetal bovine serum, 2 mmol/L L-glutamine,
100 units/mL penicillin, and 100 mg/mL streptomycin at
37°C in 50 mL/L CO2.
First Experiment
Neuropathic Cancer Pain Model
To determine the optimal number of S-180 cells that
could induce a neuropathic cancer pain model, three dif-
ferent cell numbers (1 × 107(n = 3), 5 × 106(n = 3), and 2
× 106(n = 3)) of S-180 cancer cells were inoculated into
the muscular tissue in the immediate vicinity of the nerve
near the trochanter, immediately distal to where the pos-
terior biceps semitendinosus branches off the common
sciatic nerve. Thereafter, neuropathic cancer pain was
comparatively monitored in S-180 treated groups.
MRI Scanning
MRI scanning was performed to confirm the presence of
the tumor mass around the sciatic nerve by anatomical
examination. On days 10, 16 and 24 after inoculation, the
mice from each group were sacrificed and scanned around
the sciatic nerve by MRI.
2nd Experiment
Neuropathic Cancer Pain Model
Based the number of cells required to create a successful
neuropathic cancer pain model, 2 × 106 S-180 cancer cells
were inoculated into the muscular tissue in the immediate
vicinity of the nerve near the trochanter, immediately dis-
tal to where the posterior biceps semitendinosus branches
off the common sciatic nerve (Fig. 1A and 1B).
EA Treatment
EA treatment was applied to the EA group only. A stainless
steel needle with 0.3 mm diameter was inserted at a depth
of 5 mm into the unilateral acupuncture point ST36
(Zusanli) located 0.5 cm below the fibular head of the
hinder leg in mice and stimulated with an intensity of 2
Hz (<3 mA) for 30 min daily. The levels of EA treatment
were based on values previously reported [10,17]. The
proximal end was soldered to a wire that was connected to
one of the output channels of an electric stimulator, PG-
306 (YoungMok, Japan). As shown Fig. 3, the ST36
(Zusanli) acupoint was located 5 mm below and lateral to
the anterior tubercle of the tibia. Electrical stimulation
was applied to ST36 point using two outlets via two nee-
dles. An electrical pulse with a voltage of 3–5 V, a durationJournal of Experimental & Clinical Cancer Research 2009, 28:102 http://www.jeccr.com/content/28/1/102
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A: Experimental scheme for EA treatment in a neuropathic cancer pain model, B: Neruopathic cancer pain model Figure 1
A: Experimental scheme for EA treatment in a neuropathic cancer pain model, B: Neruopathic cancer pain 
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of 0.25 ms and a frequency of 2 Hz was delivered from an
EA stimulator. The intensity of stimulation was deter-
mined to be minimum voltage to cause moderate muscle
contraction.
Behavioral Test (Mechanical von Frey test)
During a behaviour test, all mice were divided into three
groups including a tumor control group (n = 8), EA-
treated group (n = 8) and normal group (n = 8). All mice
were placed on a wire mesh platform that was fixed in a
transparent plexiglass chamber (20 × 10 × 5 cm). This
study was performed based on a modified protocol [17].
Behaviour assessment was performed on days 1, 3, 5, 7
and 9 after tumor inoculation. A series of von Frey hairs
was applied from below the wire mesh platform to the
plantar surface of the left hind paw. The hind paw with-
drawal threshold was determined using von Frey hairs
weighing from 0.4 g to 4 g. Behavioural tests using von
Frey hair on the hind paw of mice were carried out five
times in 5 s intervals. A withdrawal response was consid-
ered valid only if the hind paw was completely removed
from the wire mesh platform.
Spontaneous Pain Test
The mice from all three groups were observed for signs of
mechanical allodynia as spontaneous pain on days 3, 5, 7
and 9 after tumor inoculation. A spontaneous pain test
was performed in all the animals placed in a clear plastic
chamber with wire grid floors at room temperature. After
approximately 1 h acclimatization, the cumulative dura-
tion of hind paw-lifting of each mouse was analyzed for
10 min. The test consisted of evoking a hind paw flexion
reflex with a hand-held force transducer (electronic anaes-
thesiometer, IITC Life science, Woodland Hills, CA, USA)
adapted with a 0.5 mm2 polypylene tip. The investigator
was trained to apply the tip perpendicularly to the central
area of the hind paw with a gradual increase in pressure.
The end point was characterized by withdrawal of the paw
followed by clear lifting and flinching behaviour in the
animal. The lifting of the paw as part of grooming behav-
iour was not taken into account.
Immunohistochemistry
The specimens of spinal cord dorsal horn of mice were
sectioned on a cryostat as 40 μm coronal sections between
L3-L5. The sectioned tissues were rinsed in phosphate
buffered saline (PBS) with Tween 20 (PBST) about 3 times
before use. PBST contains 3.2 mM Na2HPO4, 0.5 mM
KH2PO4, 1.3 mM KCl, 135 mM NaCl, 0.05% Tween 20,
pH 7.4. For immunoassays, the primary antibody was
diluted with blocking solution (Vector Laboratories, Burl-
ingame, CA) and tissues were incubated with antibodies
against substance P (Abcam Ltd., Cambridge, UK) in a
1:50 ratio, for 48 h at room temperature, with constant
agitation. After rinsing in PBS, the sections were incubated
for 2 h with the biotinylated rabbit anti-serum (Vector
Laboratories, Burlingame, CA) that was diluted to 1:200
in PBST containing 1% normal goat serum. The sections
were placed in the Vectastatin™ Elite ABC reagent (Vector
Lab., UK) for 1 h. After further rinsing in PBS, the tissues
were developed using diaminobenzadine as a chromogen
with nickel intensification. These slides were air-dried,
cover-slipped and then observed under a light microscope
(Carl Zeiss, Germany).
Enzyme Immunoassay
Blood samples (1 mL) were collected into lavender vacu-
tainer tubes containing EDTA. The tubes were gently
rocked several times immediately after collection of blood
for anti-coagulation. Blood was transferred from the lav-
ender vacutainer tubes to centrifuge tubes containing
aprotinin (0.6 TIU/mL of blood) and gently rocked sev-
eral times to inhibit proteinase activity. The blood was
centrifuged at 1,600 × g for 15 min at 4°C and the plasma
was collected. Brain tissues were ground using a Teflon
Homogenizer in 2 mL lysis buffer (10 mM Tris-Hcl, pH
7.4) and centrifuged at 12,000 × g for 15 min at 4°C and
the supernatant was collected. Plasma and brain samples
were stored at -20°C prior to EIAs and then warmed up to
4°C before analysis. The samples were acidified with an
equal volume of buffer A (250 μL), centrifuged at 17,000
× g for 20 min at 4°C and equilibrated using SEP-COL-
UMN (CA, USA) containing 200 mg of C18 (Code RK-
SEPCOL-1) by washing once with buffer B (1 mL) fol-
lowed by three washes with buffer A (3 mL). The acidified
plasma solution was added to the pre-treated C-18 SEP-
COLUMN. The column was slowly washed with buffer A
(3 mL, twice). The peptide was slowly eluted with buffer
B (3 mL, once), collected into a polystyrene tube and
evaporated to dryness. The levels of β-endorphin were
measured using a direct β-endorphin EIA kit from Phoe-
nix Pharmaceuticals (CA, USA).
Statistical analysis
The data were presented as means ± SD or SE. Student's t
test was used for von Frey hair test and a one-way analysis
of variance (ANOVA) test was also conducted for immu-
nohistochemistry and β-endorphin assay.
Results
Morphological changes of S-180 tumor mass around 
sciatic nerve and induction of neuropathic cancer pain
As shown in Fig. 2A, S-180 cells grow rapidly and embed-
ded around the sciatic nerve in a time-dependent manner,
which was confirmed by MRI scanning. On day 9 after
inoculation, the sciatic nerve was partially embedded by
an S-180 tumor mass and on day 24, the sciatic nerve was
almost surrounded by the S-180 tumor mass. As shown in
Fig. 2B, among the three groups studied (1 × 107, 5 × 106
and 2 × 106 injected groups), neuropathic cancer pain wasJournal of Experimental & Clinical Cancer Research 2009, 28:102 http://www.jeccr.com/content/28/1/102
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most steadily induced in 2 × 106 injected group 2 days
after inoculation, suggesting that the suitable cell number
that induced neuropathic cancer pain was 2 × 106.
Effect of EA treatment on neuropathic cancer pain
As shown in Fig. 3A, EA treatment significantly attenuated
paw lifting latency induced 3 days after inoculation by the
von Frey test. As shown in Fig. 3B, hind paw-lifting in the
tumor control group became apparent when compared to
the normal group from day 5 after tumor inoculation and
the cumulative paw-lifting duration reached a peak on
day 9 where all the mice in the tumor control group
showed a slight foot drop in the left hind limb. On the
contrary, EA treatment significantly reduced cumulative
lifting duration compared to the untreated tumor control
group.
Effect of EA treatment on substance P and β-endorphin
Nine days after inoculation, immunohistochemistry was
performed using antibodies against substance P, in sec-
tions of spinal cord dorsal horn of mice. As shown in Fig.
4A, substance P was overexpressed in the tumor control
group compared to that of the normal control, suggesting
that the tumor mass could activate neuropathic pain-
related proteins. On the contrary, EA treatment for 9 days
effectively reduced the expression of pain peptide sub-
stance P in the dorsal horn section of the spinal cord of
mice compared to the untreated tumor control group. To
elucidate its analgesic mechanism, the levels of β-endor-
phin in blood and brain tissues of mice were analyzed
after EA treatment. As shown in Fig. 4B, the level of β-
endorphin in blood samples of the tumor control group
was significantly increased up to 2.8754 ± 0.0278 ng/mL
compared to that of the normal group, 1.3236 ± 0.0041.
On the contrary, EA treatment significantly increased the
β-endorphin levels up to 4.355 ± 0.2972 ng/mL more
than the tumor control group, 2.8754 ± 0.0278 ng/mL.
Consistently, as shown in Fig. 4C, the level of β-endor-
phin in the brain tissues of mice within the tumor control
group was significantly increased up to 4.0115 ± 0.3848
ng/mL compared to that of the normal group, 2.668 ±
1.069 ng/mL. In contrast, EA treatment significantly
increased the level of β-endorphin up to 9.0847 ± 0.5901
ng/mL more than that of the tumor control group, 4.0115
± 0.3848 ng/mL.
Discussion
Pain is an important symptom in cancer patients. The
prevalence of pain depends on tumor type and varies from
5% in patients with leukemia to 52% in patients with lung
cancer. The causes of pain are the tumor itself by bone
invasion, compression of the spinal cord or neural struc-
tures and pressure on hollow organs [6]. Thus, in the cur-
rent study, we set up a neuropathic cancer mouse model
by inoculation of S-180 tumor cells around the sciatic
nerve of mice tumor mass.
MRI scanning revealed the tumor size and position
around sciatic nerve of mice. Ten days after inoculation,
the tumor mass was shown to surround half the area
around the sciatic nerve while 24 days after inoculation,
the S-180 tumor cells embedded most of the gluteal area,
inducing neuropathic pain by compression of the sciatic
nerve [18].
A behavioural test using von Frey hairs showed that a
tumor mass of S-180 cells significantly induced paw hind
A: MRI scans of S-180 tumor mass around the sciatic nerve Figure 2
A: MRI scans of S-180 tumor mass around the sciatic 
nerve. After inoculation of S-180 tumor cells around the sci-
atic nerve, MRI scan was performed. (a) On inoculation day 
(b) 10 days after inoculation (c) 16 days after inoculation (d) 
24 days after inoculation. B: S-180 implantation around 
sciatic nerve-induced neuropathic cancer pain 
according to cell number in a time course study. 
Withdrawal latency of left hind paws was measured every 2 
days until 17 days after inoculation. Values are expressed 
means ± SE. Statistically significant differences were recorded 
after comparison to the control using the student's t test (* p 
< 0.05, ** p < 0.01).Journal of Experimental & Clinical Cancer Research 2009, 28:102 http://www.jeccr.com/content/28/1/102
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A: EA treatment increased paw withdrawal latency compared to that of the untreated tumor control Figure 3
A: EA treatment increased paw withdrawal latency compared to that of the untreated tumor control. Paw 
withdrawal latency was measured every 2 days until 9 days after inoculation. Statistically significant differences were obtained, 
in comparison to the normal control group using the student's t test (* p < 0.05). B: EA treatment reduced cumulative 
lifting duration of paw compared to untreated tumor control. Cumulative lifting duration of the left hind paws was 
measured every 2 days until 9 days after inoculation. Statistically significant differences were compared to the normal group 
using the student's t test (* p < 0.05).Journal of Experimental & Clinical Cancer Research 2009, 28:102 http://www.jeccr.com/content/28/1/102
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A: Representative photographs of a coronal section showing SP expression in the spinal cord Figure 4
A: Representative photographs of a coronal section showing SP expression in the spinal cord. Photographs (200 
×) illustrate SP immunoreactive neurons in the mouse superficial dorsal horn (SDH) of L3–5 levels. (a) Control, (b) Tumor 
control, (c) EA treated group. Arrows indicate SP positive cells. B&C: EA treatment increased the level of β-endorphin in 
blood and brain compared to untreated tumor control. B: level of β-endorphin in blood C: level of β-endorphin in 
brain. Values of β-endorphin are expressed as means ± SE. Different superscripts(a, b, c) indicate p < 0.05 statistical signifi-
cance between groups using ANOVA test-Turkey's procedure.Journal of Experimental & Clinical Cancer Research 2009, 28:102 http://www.jeccr.com/content/28/1/102
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lifting from 3 days after inoculation and prolonged cumu-
lative lifting duration as a spontaneous pain 5–9 days
after inoculation, suggesting that the neuropathic cancer
pain mouse model was successfully set up for cancer pain
assessment. In contrast, Shimoyama's cancer model that
was produced by inoculation of Meth-A sarcoma cells to
the vicinity of the sciatic nerve [19] showed that hind
paw-lifting, a behavioural sign of spontaneous pain, was
at a maximum on day 18 after inoculation of Meth-A sar-
coma cells to the vicinity of the sciatic nerve. Therefore,
our cancer pain model may induce neuropathic cancer
pain more rapidly and consistently within ten days after S-
180 cell inoculation compared to Shimoyama's cancer
model. These data strongly suggest that our cancer model
can be applied for evaluation of in vivo cancer pain control
efficacy within a short time.
To confirm the roles of pain-related peptides during acu-
puncture-induced analgesia, immunohistochemical anal-
ysis for substance P and enzyme immunoassay for β-
endorphin in blood and brain samples of mice were per-
formed in the spinal cord dorsal horn of mice. Substance
P is a neuropeptide involved in the transmission of pain
impulses from the peripheral receptors to the central nerv-
ous system. It belongs to the tachykinin neuropeptide
family [20]. EA treatment downregulated the expression
of substance P [21], while substance P was overexpressed
in the dorsal horn of the tumor control group 9 days after
inoculation [22,23].
Endorphins are endogenous opioid polypeptides released
in the pituitary gland and the hypothalamus during stren-
uous exercise and excitement. Although the role of plasma
β-endorphin in pain regulation is unclear, these mole-
cules have been reported to correlate inversely with pain
levels in cancer pain [24]. In the current study, β-endor-
phin levels were unexpectedly released twice as much in
the blood and brain samples of the tumor control animals
than in the normal group. The β-endorphin that is
released into the blood cannot enter the brain in large
quantities because of the blood-brain barrier [8]. On the
contrary, EA treatment significantly increased β-endor-
phin levels compared to that of the tumor control group.
These data support involvement of the endorphin system
in the neuropathic cancer pain model presented in this
study.
In summary, a mass of S-180 cancer cells was embedded
around the sciatic nerve as shown by time course MRI
scanning. Mechanical allodynia was most consistently
induced in the S-180 (2 × 106)-treated group among all
the groups studied. In contrast, EA treatment significantly
prolonged the paw withdrawal latency and shortened the
cumulative lifting duration compared to the S-180 tumor
control group. In addition, the overexpression of pain
peptide substance P in the dorsal horn of the spinal cord
was significantly decreased in the EA-treated group com-
pared to the S-180 tumor control group, 9 days after inoc-
ulation. Furthermore, EA treatment effectively increased
the concentration of β-endorphin in the blood and brain
of mice compared to the S-180 tumor control group.
Conclusion
The findings in the current study suggest that a S-180 can-
cer pain model can be a consistent and short time animal
model and EA treatment also can be used as an alternative
therapeutic method for cancer pain via decrease of sub-
stance P and increase of β-endorphin.
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